Antimicrobial Susceptibility Test Market

Because Section 511A of the US Federal Food, Drug, and Cosmetic Act lets device makers cite the breakpoints that the US Food and Drug Administration (FDA) lists on its Susceptibility Test Interpretive Criteria (STIC) website, launched by Federal Register notice on 13 December 2017, antimicrobial susceptibility test panels now track new drug cut-offs within months. The antimicrobial susceptibility test market covers the panels, cards, discs, gradient strips, microdilution plates, instruments and software that clinical laboratories use to tell clinicians which antibiotics will work against a cultured pathogen. Douglas Insights sizes it at USD 3.92 billion in 2025: 268.4 million antimicrobial susceptibility testing (AST) runs at an average USD 14.62 each. Revenue reaches USD 6.92 billion by 2035, a 5.83% annual pace built from 4.35% volume growth and 1.42% price growth. The study belongs to our in-vitro diagnostics coverage, and every step of the build follows the Douglas Insights research methodology.

Who supplies antimicrobial susceptibility test systems, and how concentrated is the competition?

Three suppliers hold about 69.6% of 2025 antimicrobial susceptibility test revenue, by Douglas Insights estimate: bioMérieux, the Phoenix franchise now inside Waters, and Beckman Coulter with MicroScan. Their lead rests on installed automated instruments, because every placed analyser locks in years of proprietary panel or card purchases.

bioMérieux leads with an estimated 34.6% share, or about USD 1.36 billion of antimicrobial susceptibility test sales. Its VITEK 2 card reader holds 60 cards, the XL version 120, and the company lists susceptibility menus covering up to 180 antimicrobials. bioMérieux bought Specific Diagnostics in 2022 and won FDA 510(k) clearance for the resulting VITEK REVEAL system on 21 June 2024, with Gram-negative results from positive blood cultures in an average 5.5 to 6 hours. Group sales reached EUR 4.07 billion in 2025, yet its 27 February 2026 results booked a partial impairment of the REVEAL technology and a double-digit fall in China microbiology.

Waters now owns the BD Phoenix line after its Reverse Morris Trust combination with BD’s biosciences and diagnostic solutions businesses closed. The Phoenix M50 instrument stacks two units in one footprint; its panels carry 85 antimicrobial dilution wells, and the Emerge panel 136 wells. Douglas Insights puts the franchise at 19.8% of antimicrobial susceptibility test revenue. Beckman Coulter follows at an estimated 15.2%, selling MicroScan panels on the DxM MicroScan WalkAway, often paired with the Bruker MALDI Biotyper for identification in its DxM Trio bundle.

Thermo Fisher Scientific takes about 9.7% through Sensititre broth microdilution plates, which it describes as the gold-standard method, with more than 300 antimicrobials available for custom plates. Bruker supplies matrix-assisted laser desorption/ionisation (MALDI) identification that sits upstream of almost every automated AST run. Q-linea of Sweden sells the FDA-cleared ASTar rapid platform. Accelerate Diagnostics, an early rapid-AST name, agreed to sell substantially all assets to Indaba Capital for a USD 36.9 million credit bid inside Chapter 11. The remaining 20.7% is spread across these challengers and regional disc makers.

Which antimicrobial susceptibility test product segment makes the money?

Automated AST panels and cards earn USD 1.76 billion, or 44.8% of 2025 antimicrobial susceptibility test revenue, because each placed VITEK, Phoenix or MicroScan analyser consumes a proprietary panel for every isolate. Rapid phenotypic AST from positive blood cultures grows fastest, at 14.41% a year.

Automated AST panels and cards rise from USD 1.76 billion to USD 2.95 billion at 5.31%, since a 120-card VITEK 2 XL or a stacked Phoenix pair turns each new installation into a decade of consumable demand. Disc diffusion and gradient strips hold USD 702.4 million at 17.9%: cheap, flexible and standard in smaller laboratories, they grow only 2.74% as automation absorbs routine isolates. Broth microdilution MIC plates carry USD 525.8 million and grow 5.66%, as reference laboratories run minimum inhibitory concentration (MIC) work on new beta-lactam combinations before automated panels add them.

AST instruments and software total USD 514.0 million, 13.1% of value, growing 4.12% on replacement cycles and middleware upgrades. Molecular resistance marker assays, at USD 176.6 million, grow 8.93% as carbapenemase gene detection moves earlier in the workflow. Rapid phenotypic AST from positive blood cultures is the smallest phenotypic line at USD 247.2 million, yet climbs to USD 949.9 million by the end of the decade, because a 6-hour result lets sepsis teams change therapy the same day.

Why are hospital laboratories buying more antimicrobial susceptibility tests every year?

Antimicrobial susceptibility test volumes grow 4.35% a year because resistance keeps rising, blood-culture workflows are accelerating and breakpoint revisions keep expanding panel menus. Douglas Insights splits that volume leg into four contributions worth 1.62, 1.18, 0.94 and 0.61 points.

Resistance itself adds 1.62 points. The World Health Organization (WHO) reported on 13 October 2025 that about 1 in 6 laboratory-confirmed bacterial infections in 2023 resisted treatment, with resistance rising in over 40% of monitored pathogen and antibiotic pairs between 2018 and 2023 at 5% to 15% a year. Reporting countries in its Global Antimicrobial Resistance and Use Surveillance System (GLASS) grew from 25 in 2016 to 104 in 2023. Each newly reporting laboratory adds culture and antimicrobial susceptibility test volume, and each resistant isolate often triggers a second panel or a gradient strip confirmation.

Faster blood-culture results add 1.18 points. bioMérieux cites 11 million sepsis deaths a year worldwide, 1.3 million of them attributable to resistant bacteria, in its 21 June 2024 VITEK REVEAL clearance release. Same-day AST from a positive bottle shifts sepsis therapy decisions by roughly a day, and our model finds about 2.5 rapid runs per 100 automated runs in 2025. Hospitals that buy a rapid system rarely drop the overnight panel, so the test count rises on both sides. A sepsis programme that adds rapid runs for 1,000 positive bottles a year still confirms most of them on its routine analyser, so one bloodstream isolate can generate two antimicrobial susceptibility test charges instead of one.

Menu expansion adds 0.94 points. FDA recognised the 36th edition of the Clinical and Laboratory Standards Institute (CLSI) M100 standard on its STIC page updated 17 June 2026, and the 13 December 2017 website launch let sponsors cite those listed criteria in premarket filings. Q-linea added 93 bug and drug combinations on 16 April 2026, taking its ASTar Gram-negative menu to 215, roughly 75% more than its first panel. Every new drug that gains an FDA-recognised breakpoint becomes another well, and another reason to repeat antimicrobial susceptibility test runs.

Laboratory build-out in Asia Pacific, the Middle East and Latin America adds the final 0.61 points. Our model puts Asia Pacific volume growth near 6.3% a year as provincial hospitals add automated identification and susceptibility lines. Together the four contributions equal the 4.35% volume leg; the 1.42% price leg comes mainly from the shift toward rapid and MIC formats.

Which headwinds slow antimicrobial susceptibility test revenue growth?

Three headwinds remove about 1.14 points from antimicrobial susceptibility test volume growth, by Douglas Insights estimate: China procurement pressure, flat laboratory budgets and the cost of failed rapid platforms. Without them the volume leg would run near 5.49% instead of 4.35%.

China pricing and procurement remove 0.48 points. bioMérieux reported 4% organic microbiology growth for 2025 but 6.3% excluding China, after a double-digit decline there, in its 27 February 2026 results release. Volume-based purchasing pushes antimicrobial susceptibility test panel prices down and delays automated placements in county hospitals.

Flat laboratory budgets and staffing remove 0.37 points. A typical high-volume United States microbiology laboratory runs about 400,000 tests a year with an 8.2% positivity rate in BD’s own workflow model, and adding a second AST platform needs bench space, validation time and technologists that many hospitals lack. Rapid platform economics remove 0.29 points: bioMérieux booked a partial impairment of VITEK REVEAL, and Accelerate Diagnostics went through Chapter 11 with a USD 36.9 million credit bid. Investors now demand proof of reimbursement before funding new rapid antimicrobial susceptibility test systems.

Where do antimicrobial susceptibility test volumes grow fastest?

North America leads with USD 1.52 billion of 2025 antimicrobial susceptibility test revenue, 38.7% of the total, while Asia Pacific grows fastest at 7.94% a year on new hospital laboratories and rising resistance. Douglas Insights expects Asia Pacific to reach USD 1.99 billion by 2035.

North America grows 5.08% to USD 2.49 billion, carried by early rapid-AST adoption, the STIC breakpoint pipeline and the more than 2.8 million resistant infections a year in Centers for Disease Control and Prevention (CDC) threat estimates. Europe holds USD 1.11 billion, 28.4%, and grows 4.71% to USD 1.77 billion; EUCAST, the European Committee on Antimicrobial Susceptibility Testing, keeps tables free to use, so disc diffusion stays common there.

Asia Pacific starts at USD 926.1 million, 23.6%, and doubles to USD 1.99 billion because India and Southeast Asia are still automating and WHO places the South-East Asia region among the highest resistance burdens, at about 1 in 3 infections. Latin America adds USD 204.0 million, 5.2%, growing 6.37% to USD 378.3 million. The wildcard is the Middle East and Africa: USD 160.9 million, 4.1%, growing 6.13% to USD 291.7 million, with WHO reporting resistance above 70% to third-generation cephalosporins in the African Region and Q-linea already shipping ASTar instruments to Saudi Arabia.

How much do laboratories pay per antimicrobial susceptibility test?

Laboratories pay an average USD 14.62 per antimicrobial susceptibility test run in 2025, by Douglas Insights estimate, rising to about USD 16.83 by 2035 at 1.42% a year. Bands run from a few dollars for discs to over USD 60 for rapid blood-culture runs.

Instrument prices are recovered through reagent rental: our model spreads analyser and software revenue across seven years of runs, adding about USD 1.92 to the blended antimicrobial susceptibility test price. Mix, not list-price inflation, drives the 1.42% price leg: rapid runs cost about 5.6 times an automated card.

Which tests and buyers does the antimicrobial susceptibility test market include?

The antimicrobial susceptibility test market includes six product groups worth USD 3.92 billion in 2025, sold to hospital laboratories, reference laboratories and pharmaceutical and research laboratories. Identification-only tests, blood culture bottles and antifungal drug sales sit outside the scope.

By application the model splits runs across bloodstream infections, urinary tract infections, respiratory infections and wound and other infections. Urine isolates supply the largest antimicrobial susceptibility test count, about 41% of runs in our model, while bloodstream isolates carry the highest value per run. Adjacent upstream spending is covered in our Blood Culture Bottle Market report, sample preparation in the Magnetic Bead-based Nucleic Acid Extraction Market study, and quality-control microbiology in the Pharma Microbiology Testing Kits Market report.

What breakpoint rules and standards govern antimicrobial susceptibility test menus?

Two breakpoint systems govern antimicrobial susceptibility test menus: the FDA STIC list in the United States, updated at least every six months, and EUCAST tables in Europe, now at version 16.1 from 24 June 2026. A panel sold without current breakpoints loses tenders.

Section 3044 of the 21st Century Cures Act, signed on 13 December 2016, added Section 511A and required FDA to open the STIC site within a year, which it did by notice on 13 December 2017. The notice lets sponsors of antimicrobial susceptibility test devices rely on listed criteria for premarket authorisation, so a manufacturer no longer waits for each drug label change. The STIC page recognises CLSI M100 (36th edition, 2026), M45 (2015), M24 (2018), M24S (2023) and M43-A (2011), with listed exceptions.

The consequence is commercial. Q-linea describes its expanded ASTar panel as conforming to the latest FDA breakpoints, and bioMérieux holds CE marking for VITEK REVEAL under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for the instrument. Douglas Insights counts five recognised CLSI documents and two EUCAST table sets in 2026, and each revision is a reason for laboratories to re-verify, and often re-buy, antimicrobial susceptibility test panels.

What happens to antimicrobial susceptibility test revenue in slower and faster cases to 2035?

Antimicrobial susceptibility test revenue lands between USD 5.66 billion and USD 8.33 billion in 2035 across our three cases, with USD 6.92 billion as the base. Rapid-AST adoption and China procurement are the two swing factors.

The slower case assumes China volume-based purchasing spreads to Southeast Asia and that more rapid platforms follow REVEAL into write-downs, cutting volume growth to 2.90% and price growth to 0.80%. The faster case assumes STIC updates keep adding new beta-lactam combinations each half-year, as the 13 December 2017 Federal Register notice allows, and that same-day blood-culture AST becomes standard in tertiary hospitals, lifting volume to 5.60% and price to 2.10%.

One extra point of annual volume growth adds about USD 692.1 million to the 2035 antimicrobial susceptibility test figure. Published forecasts sit between 5.1% and 8.8% a year; our 5.83% falls in the lower half, because we net out the China decline and treat rapid platforms as additive only where hospitals keep paying for them.

Douglas Exclusive: the Same-Shift AST Index

The Same-Shift AST Index is a Douglas Insights model, built from 14 inputs: four published turnaround times and the 2025 values and growth rates of five test segments. It measures the share of antimicrobial susceptibility test consumable spending that returns a result inside one 8-hour laboratory shift.

The four turnaround inputs are 6 to 8 hours for VITEK 2, 5.5 to 6 hours for VITEK REVEAL, about 6 hours for ASTar and 6 to 11 hours for BD Phoenix carbapenemase-producing organism (CPO) detection. Our model assigns a same-shift weight of 0.58 to automated AST panels and cards, 0.92 to rapid blood-culture runs, 0.85 to molecular marker assays and zero to disc diffusion and MIC plates, which our model treats as overnight reads. Instrument revenue is excluded, leaving USD 3.41 billion of 2025 consumable spend.

The index reads 41.0 in 2025 and 47.8 in 2035. In plain terms, 41.0% of antimicrobial susceptibility test consumable dollars already buy a same-shift answer, and the 6.8-point gain over the decade comes almost entirely from rapid blood-culture runs growing 14.41% a year. The finding: speed is spreading, but overnight methods still hold more than half of the spend by 2035.

Can rapid blood-culture AST overtake overnight antimicrobial susceptibility test panels?

No, not by 2035: rapid phenotypic AST reaches USD 949.9 million, about 32% of the USD 2.95 billion automated panel segment. Douglas Insights expects rapid systems to sit beside overnight antimicrobial susceptibility test panels rather than replace them.

Rapid runs cost about 5.6 times a standard card, and laboratories still confirm many results on their existing VITEK, Phoenix or MicroScan lines. bioMérieux’s impairment of REVEAL, Accelerate’s credit-bid sale and Q-linea’s 215-combination menu show the same pattern: menus are now broad enough, but reimbursement for a faster antimicrobial susceptibility test remains thin.

How the model reaches 268.4 million antimicrobial susceptibility test runs: what are the checks?

The model multiplies 268.4 million antimicrobial susceptibility test runs by USD 14.62 to reach USD 3.92 billion in 2025. It builds five regional models and draws on 14 sourced inputs plus 5 published growth forecasts.

Runs are built from culture positivity, isolates per positive culture and panels per isolate in each country model; price comes from the segment bands above, weighted by 2025 run mix. Volume compounds at 4.35% to 410.9 million runs by 2035 and price at 1.42% to USD 16.83, giving USD 6.92 billion. Cross-check one: the top-three share build implies bioMérieux AST sales of USD 1.36 billion, about 30% of its EUR 4.07 billion group sales at our assumed USD 1.13 per euro. Cross-check two: published 2025 market sizes run from USD 4.13 billion to USD 4.21 billion, within 7.3% of our USD 3.92 billion, which excludes identification-only products.

What should buyers of antimicrobial susceptibility test platforms watch in 2027?

Watch three signals in 2027: the next two STIC updates, bioMérieux’s China microbiology trend after its double-digit 2025 fall, and whether Waters invests in the Phoenix line. Each moves the antimicrobial susceptibility test forecast by a measurable amount.

A STIC update that recognises a new CLSI M100 edition without exceptions would support our faster menu path. A China recovery to mid-single-digit growth would add roughly 0.3 points to volume. Douglas Insights calculates that a 1-point rise in price growth alone would lift 2035 revenue by about USD 0.71 billion, slightly more than the USD 692.1 million from volume, so platform pricing under Waters ownership deserves as much attention as test counts.

Sources

1. US Federal Register / FDA 21st Century Cures Act: Announcing the Establishment of the Susceptibility Test Interpretive Criteria Website (2017)
2. US FDA Antibacterial Susceptibility Test Interpretive Criteria (2026)
3. bioMérieux VITEK REVEAL FDA 510(k) clearance (2024)
4. bioMérieux 2025 financial results (2026)
5. Q-linea FDA clearance of expanded ASTar blood testing menu (2026)
6. World Health Organization WHO warns of widespread resistance to common antibiotics worldwide (2025)
7. bioMérieux VITEK 2 product page (2026)
8. BD BD Phoenix M50 instrument (2026)
9. Thermo Fisher Scientific Antimicrobial susceptibility testing (2026)
10. Beckman Coulter Microbiology products (2026)
11. EUCAST Clinical breakpoints (2026)